Biogen Inc
January 6, 2023
[ad_1] The drug Leqembi may slightly slow cognitive decline in the early stages of the disease, but it comes with some safety risks. However, data suggests it holds more promise than the small number of other treatments available. [ad_2] Source link
December 29, 2022
[ad_1] The report said the FDA’s approval process for Aduhelm was “riddled with irregularities” and criticized Biogen for setting an “unjustifiably high price.” [ad_2] Source link
November 29, 2022
[ad_1] The drug lecanemab, made by Eisai and Biogen, also carries a risk of brain swelling and bleeding and should be investigated further, a report of the findings said. [ad_2] Source link
